Neuroprotective Effect of Intrastriatal Caffeic Acid Phenethyl Ester Treatment in 6-OH Dopamine Model of Parkinson’s Disease in Rats
Parkinson’s disease (PD) is the second most common neurodegenerative disorder, and the main cause of PD is still not known. Until now, no cure for Parkinson’s disease is yet in sight. Caffeic acid phenethyl ester (CAPE) is a polyphenolic component of the propolis, which can be derived from honeybee...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Parkinson's Disease |
| Online Access: | http://dx.doi.org/10.1155/2021/5553480 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832556610543681536 |
|---|---|
| author | Burak Cem Soner Eda Acikgoz Salim Yalcin Inan Sule Ayla Ayse Saide Sahin Gulperi Oktem |
| author_facet | Burak Cem Soner Eda Acikgoz Salim Yalcin Inan Sule Ayla Ayse Saide Sahin Gulperi Oktem |
| author_sort | Burak Cem Soner |
| collection | DOAJ |
| description | Parkinson’s disease (PD) is the second most common neurodegenerative disorder, and the main cause of PD is still not known. Until now, no cure for Parkinson’s disease is yet in sight. Caffeic acid phenethyl ester (CAPE) is a polyphenolic component of the propolis, which can be derived from honeybee hive propolis. We aimed to determine the effect of intrastriatal CAPE administration as a neuroprotective agent on 6-hydroxydopamine (6-OHDA)-induced PD model. Adult male Wistar rats weighing 280–320 g were used. The PD model was induced with unilateral intrastriatal 6-OHDA injection. Treatment groups received 20 μmol/5 μL/4 day and 80 μmol/5 μL/4 day CAPE 24 h after 6-OHDA injection. Eight days after 6-OHDA application, behavioral studies (adhesive tape removal test, open-field test, cylinder test, and apomorphine-induced asymmetric rotational behavior) were performed once more to compare the effects of CAPE on behavior tests. Striatal histological verifications, immunohistochemistry, and stereological quantitation were performed. Our results for the first time showed that, besides improving the motor performance, CAPE treatment also prevents 6-OHDA-induced loss of TH-positive neurons. From our results, CAPE may be a promising clinical agent in the treatment of PD. |
| format | Article |
| id | doaj-art-5d105157568749f5bf4972d114e48123 |
| institution | Kabale University |
| issn | 2090-8083 2042-0080 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Parkinson's Disease |
| spelling | doaj-art-5d105157568749f5bf4972d114e481232025-02-03T05:44:51ZengWileyParkinson's Disease2090-80832042-00802021-01-01202110.1155/2021/55534805553480Neuroprotective Effect of Intrastriatal Caffeic Acid Phenethyl Ester Treatment in 6-OH Dopamine Model of Parkinson’s Disease in RatsBurak Cem Soner0Eda Acikgoz1Salim Yalcin Inan2Sule Ayla3Ayse Saide Sahin4Gulperi Oktem5Izmir Democracy University, Faculty of Medicine, Department of Pharmacology, 35100 Izmir, TurkeyVan Yuzuncu Yil University, Faculty of Medicine, Department of Histology and Embryology, 65080 Van, TurkeyNecmettin Erbakan University, Meram Faculty of Medicine, Department of Medical Pharmacology, 42100 Konya, TurkeyIstanbul Medipol University, School of Medicine, Department of Histology and Embryology, İstanbul, TurkeyNecmettin Erbakan University, Meram Faculty of Medicine, Department of Medical Pharmacology, 42100 Konya, TurkeyEge University, Faculty of Medicine, Department of Histology and Embryology, 35100 Izmir, TurkeyParkinson’s disease (PD) is the second most common neurodegenerative disorder, and the main cause of PD is still not known. Until now, no cure for Parkinson’s disease is yet in sight. Caffeic acid phenethyl ester (CAPE) is a polyphenolic component of the propolis, which can be derived from honeybee hive propolis. We aimed to determine the effect of intrastriatal CAPE administration as a neuroprotective agent on 6-hydroxydopamine (6-OHDA)-induced PD model. Adult male Wistar rats weighing 280–320 g were used. The PD model was induced with unilateral intrastriatal 6-OHDA injection. Treatment groups received 20 μmol/5 μL/4 day and 80 μmol/5 μL/4 day CAPE 24 h after 6-OHDA injection. Eight days after 6-OHDA application, behavioral studies (adhesive tape removal test, open-field test, cylinder test, and apomorphine-induced asymmetric rotational behavior) were performed once more to compare the effects of CAPE on behavior tests. Striatal histological verifications, immunohistochemistry, and stereological quantitation were performed. Our results for the first time showed that, besides improving the motor performance, CAPE treatment also prevents 6-OHDA-induced loss of TH-positive neurons. From our results, CAPE may be a promising clinical agent in the treatment of PD.http://dx.doi.org/10.1155/2021/5553480 |
| spellingShingle | Burak Cem Soner Eda Acikgoz Salim Yalcin Inan Sule Ayla Ayse Saide Sahin Gulperi Oktem Neuroprotective Effect of Intrastriatal Caffeic Acid Phenethyl Ester Treatment in 6-OH Dopamine Model of Parkinson’s Disease in Rats Parkinson's Disease |
| title | Neuroprotective Effect of Intrastriatal Caffeic Acid Phenethyl Ester Treatment in 6-OH Dopamine Model of Parkinson’s Disease in Rats |
| title_full | Neuroprotective Effect of Intrastriatal Caffeic Acid Phenethyl Ester Treatment in 6-OH Dopamine Model of Parkinson’s Disease in Rats |
| title_fullStr | Neuroprotective Effect of Intrastriatal Caffeic Acid Phenethyl Ester Treatment in 6-OH Dopamine Model of Parkinson’s Disease in Rats |
| title_full_unstemmed | Neuroprotective Effect of Intrastriatal Caffeic Acid Phenethyl Ester Treatment in 6-OH Dopamine Model of Parkinson’s Disease in Rats |
| title_short | Neuroprotective Effect of Intrastriatal Caffeic Acid Phenethyl Ester Treatment in 6-OH Dopamine Model of Parkinson’s Disease in Rats |
| title_sort | neuroprotective effect of intrastriatal caffeic acid phenethyl ester treatment in 6 oh dopamine model of parkinson s disease in rats |
| url | http://dx.doi.org/10.1155/2021/5553480 |
| work_keys_str_mv | AT burakcemsoner neuroprotectiveeffectofintrastriatalcaffeicacidphenethylestertreatmentin6ohdopaminemodelofparkinsonsdiseaseinrats AT edaacikgoz neuroprotectiveeffectofintrastriatalcaffeicacidphenethylestertreatmentin6ohdopaminemodelofparkinsonsdiseaseinrats AT salimyalcininan neuroprotectiveeffectofintrastriatalcaffeicacidphenethylestertreatmentin6ohdopaminemodelofparkinsonsdiseaseinrats AT suleayla neuroprotectiveeffectofintrastriatalcaffeicacidphenethylestertreatmentin6ohdopaminemodelofparkinsonsdiseaseinrats AT aysesaidesahin neuroprotectiveeffectofintrastriatalcaffeicacidphenethylestertreatmentin6ohdopaminemodelofparkinsonsdiseaseinrats AT gulperioktem neuroprotectiveeffectofintrastriatalcaffeicacidphenethylestertreatmentin6ohdopaminemodelofparkinsonsdiseaseinrats |